Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
2.
Ann Fr Anesth Reanim ; 30(9): 665-78, 2011 Sep.
Artigo em Francês | MEDLINE | ID: mdl-21764247

RESUMO

OBJECTIVE: Damage control is a strategy of care for bleeding trauma patients, involving minimal rescue surgery associated to perioperative resuscitation. The purpose of this review is to draw up a statement on current knowledge available on damage control. DATA SOURCES: References were obtained from recent review articles, personal files, and Medline database research of English and French publications. All categories of articles on this topic have been selected. DATA SYNTHESIS: Historical damage control surgery, that consist of abbreviated laparotomy with second-look after resuscitation, is now included in a wider concept called "damage control resuscitation", addressing the lethal triad (coagulopathy, hypothermia and acidosis) at an early phase. Care is focused on coagulopathy prevention. Early resuscitation, or damage control ground zero, has been improved: aggressive management of hypothermia, bleeding control techniques, permissive hypotension concept and early use of vasopressors. Transfusion practices also have evolved: early platelets and coagulation factors administration, use of hemostatic agents like recombinant FVIIa, whole blood transfusion, denote the damage control hematology. Progress in surgical practices and development of arteriographic techniques lead to wider indications of damage control strategy.


Assuntos
Tratamento de Emergência/métodos , Ressuscitação/métodos , Ferimentos e Lesões/terapia , Acidose/complicações , Acidose/terapia , Transtornos da Coagulação Sanguínea/complicações , Transtornos da Coagulação Sanguínea/terapia , Embolização Terapêutica , Serviços Médicos de Emergência , Hemostasia , Hemostáticos/uso terapêutico , Humanos , Hipotermia/complicações , Hipotermia/terapia , Laparotomia , Assistência Perioperatória , Procedimentos Cirúrgicos Operatórios , Vasoconstritores/uso terapêutico , Ferimentos e Lesões/fisiopatologia
3.
Med Mal Infect ; 40(2): 94-9, 2010 Feb.
Artigo em Francês | MEDLINE | ID: mdl-19793633

RESUMO

OBJECTIVES: This monocentric, observational and retrospective survey was performed to check the appropriateness between aminoglycoside prescriptions and inhibitor quotient to be reached, in Intensive Care Unit (ICU) patients. We identified variability factors for aminoglycoside plasmatic concentrations at peak such as standardized index of gravity (IGS2 scale), age, sex, weight, and severity of sepsis. PATIENTS AND METHOD: Eighty-seven ICU patients received an antibiotic combination mandatorily including an aminoglycoside (amikacin or gentamicin) as curative treatment for a severe infection. Prescribed dosages were 15mg/kg for amikacin and 5mg/kg for gentamicin. The maximal concentration (Cmax) and minimal inhibiting concentration (MIC) of involved bacteria were recorded. The aminoglycoside ratio Cmax/MIC, called inhibitor quotient, was determined. The inhibitor quotient was considered efficient when superior to 10. The Cmax for aminoglycoside first peak was also compared with the theoretical Cmax to be reached. RESULTS: In the aminoglycoside Cmax, 50.3% were efficient (59.6% for amikacin Cmax and 38.9% for gentamicin Cmax). In 46% of the cases, the inhibitor quotient was efficient; 12.6% of Cmax reached the theoretical Cmax. Factors identified as negatively interacting with biological efficiency were: Gram-positive bacteria or anaerobic bacteria infections and planned surgery. CONCLUSION: In the inhibitor quotients, 49.7% were at inefficient rates, even when the recommended aminoglycoside dosage for was given. Therefore, dose and administration should be updated.


Assuntos
Amicacina/sangue , Antibacterianos/sangue , Monitoramento de Medicamentos , Gentamicinas/sangue , Unidades de Terapia Intensiva , Adulto , Idoso , Idoso de 80 Anos ou mais , Amicacina/uso terapêutico , Antibacterianos/uso terapêutico , Feminino , Gentamicinas/uso terapêutico , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...